Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
GSK posts phase 3 itch data as it closes in on FDA approval
GSK said patients on linerixibat reported reductions in itching that began after two weeks and persisted through the 24-week primary endpoint.
Nick Paul Taylor
May 8, 2025 8:50am
CRISPR Tx sees 80% fall in LDL, triglycerides after in vivo edit
May 7, 2025 10:00am
Marea rises toward phase 2b after posting cholesterol data
May 7, 2025 8:25am
PTC and Novartis’ Huntington's data fail to convince investors
May 6, 2025 7:25am
Aldeyra posts hit, miss for dry eye drug, plans FDA filing
May 6, 2025 7:05am
J&J gene therapy fails ph. 3 rare eye disease trial
May 5, 2025 11:33am
